Ask AI
ProCE Banner Activity

Heart Failure Decision Lab: An Expert Masterclass in Integrating Biology, Diagnostics, and Evidence-Based Therapy

Slideset

It is essential that healthcare professionals recognize and connect heart failure biology across the ejection fraction spectrum, which can be done with early evaluation, risk stratification, and phenotyping. Use these slides to learn best practices in diagnosing and treating heart failure, including strategies for translating the latest evidence into your clinical practice and providing guideline-directed medical therapy as indicated.

Released: October 07, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This activity is intended for healthcare professionals involved in the diagnosis and management of heart failure (including patients with metabolic or kidney comorbidities), including cardiologists, heart failure specialists, and cardiology-focused advanced practice providers (NPs/PAs).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current understanding of heart failure pathophysiology across the ejection fraction spectrum, including neurohormonal and cardiometabolic mechanisms, to inform clinical evaluation and risk stratification

  • Integrate contemporary diagnostic strategies, including biomarkers, advanced imaging, and validated clinical scoring systems, to identify heart failure earlier in disease progression and support accurate phenotyping

  • Implement guideline-directed medical therapy (GDMT) for patients with heart failure by strategically initiating, titrating, and sequencing evidence-based treatments in alignment with current guideline recommendations, while addressing cardiometabolic comorbidities and managing treatment-related adverse effects

Financial Disclosures

Primary Author

Chris M. Bell, ACNP: consultant/advisor/speaker: Alnylam, AstraZeneca, Bristol Myers Squibb, BridgeBio, CVRz, Cytokinetics, Milestone.

Ty J. Gluckman, MD, MHA: consultant/advisor/speaker: OptumRx.

Ahmad Masri, MD, MS: researcher: Attralus, Bayer, Cytokinetics, Janssen; consultant: Akros, Alexion, Alnylam, AstraZeneca, Attralus, Avidity, Bayer, BioMarin, Braveheart, BridgeBio, Cytokinetics, Edgewise, Haya, Imbria, Ionis, Lexeo, Lexicon, Neurimmune, Pfizer, Prothena, Rocket.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for drafting educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.